-

Global Transdermal Scopolamine Market to Reach $528.5 Million by 2027 at a 5.3% CAGR - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Transdermal Scopolamine: Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.

Global Transdermal Scopolamine Market to Reach $528.5 Million by 2027

In the changed post COVID-19 business landscape, the global market for Transdermal Scopolamine estimated at US$368.7 Million in the year 2020, is projected to reach a revised size of US$528.5 Million by 2027, growing at a CAGR of 5.3% over the analysis period 2020-2027.

The U.S. Market is Estimated at $108.7 Million, While China is Forecast to Grow at 4.9% CAGR

The Transdermal Scopolamine market in the U.S. is estimated at US$108.7 Million in the year 2020. China, the world's second largest economy, is forecast to reach a projected market size of US$93.2 Million by the year 2027 trailing a CAGR of 4.9% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5% and 4.2% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 4.4% CAGR.

Select Competitors (Total 41 Featured) -

  • Alchem International
  • Alkaloids of Australia
  • ALZA Corporation
  • Baxter International Inc.
  • Caleb Pharmaceuticals Inc
  • Centroflora-Cms
  • Fine Chemicals Corporation
  • GlaxoSmithKline Plc
  • Myungmoon Pharma Co. Ltd.
  • Novartis AG
  • Perrigo Co. Plc
  • Phytex Australia

Key Topics Covered:

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

  • Influencer Market Insights
  • World Market Trajectories
  • Transdermal Scopolamine - Global Key Competitors Percentage Market Share in 2022 (E)
  • Impact of Covid-19 and a Looming Global Recession
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE

III. MARKET ANALYSIS

IV. COMPETITION

Companies Mentioned

  • Alchem International
  • Alkaloids of Australia
  • ALZA Corporation
  • Baxter International Inc.
  • Caleb Pharmaceuticals Inc
  • Centroflora-Cms
  • Fine Chemicals Corporation
  • GlaxoSmithKline Plc
  • Myungmoon Pharma Co. Ltd.
  • Novartis AG
  • Perrigo Co. Plc
  • Phytex Australia

For more information about this report visit https://www.researchandmarkets.com/r/mjl3iv

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Research and Markets


Release Versions

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

More News From Research and Markets

Malaysia Defense Industry Report 2025: $4.8 Billion Allocation in 2025 Reflects 6.0% CAGR Growth Momentum - Forecast to 2030 - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Malaysia Defense Market - Size and Trends, Budget Allocation, Regulations, Key Acquisitions, Competitive Landscape and Forecast, 2025-2030" report has been added to ResearchAndMarkets.com's offering. The report provides the market size forecast and the projected growth rate for the next five years. The report covers industry analysis including the key market drivers, emerging technology trends, and major challenges faced by market participants. It also offers insig...

France Defense Industry Report 2025: Defense Expenditure Driven by Domestic Modernization Programs, Russia and the Invasion of Ukraine and NATO Alliance - Forecast to 2030 - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "France Defense Market - Size and trends, budget allocation, regulations, key acquisitions, competitive landscape and forecast, 2025-2030" report has been added to ResearchAndMarkets.com's offering. The report provides the market size forecast and the projected growth rate for the next five years. The report covers industry analysis including the key market drivers, emerging technology trends, and major challenges faced by market participants. It also offers insight...

$43.4 Bn Orphan Drugs Service Markets 2019-2024, 2024-2029F, 2034F - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Orphan Drugs Service Market Report 2025" has been added to ResearchAndMarkets.com's offering. The global orphan drugs service market is witnessing unprecedented growth, reflecting the increasing focus on rare diseases, investment in biopharmaceutical research, and enhanced collaborations between healthcare providers and researchers. From $37.05 billion in 2024, the market is projected to soar to $43.4 billion by 2025, with a robust CAGR of 17.1%. Growth drivers inc...
Back to Newsroom